about
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumorsPD-1 inhibition and treatment of advanced melanoma-role of pembrolizumabTLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10The use of immunotherapy in the treatment of melanomaThe human application of gene therapy to re-program T-cell specificity using chimeric antigen receptorsA novel and effective cancer immunotherapy mouse model using antigen-specific B cells selected in vitroPrognostic significance of the neutrophil-to-lymphocyte ratio in primary liver cancer: a meta-analysis.Prognostic significance of the neutrophil to lymphocyte ratio in patients with non-small cell lung cancer: a systemic review and meta-analysis.Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model.The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytesIpilimumab reshapes T cell memory subsets in melanoma patients with clinical response.Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma.Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy.Immunotherapy of melanoma: present options and future promises.Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.Making urothelial carcinomas less immune to immunotherapy.Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity.Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types.An adaptive immune response driven by mature, antigen-experienced T and B cells within the microenvironment of oral squamous cell carcinoma.Immuno-oncology in urothelial carcinoma: who or what will ultimately sit on the iron throne?Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor).High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2
P2860
Q26741260-8BFCCADD-95B7-4A3D-BA23-7697888D1CAEQ28073874-434115B6-4085-4D4B-9E80-22C3D1816479Q30300383-F4B09726-B055-469D-8E19-AD709A5B9DDEQ33593858-CA6664D6-659C-475A-AD66-B148B357399EQ34309388-FACB3151-67B8-4E99-8C6F-97D70B6859F8Q35125204-825F5DB7-1AD1-4DE7-9872-C7FFDAF4786EQ35161694-0A8A64A0-3607-43DD-9131-5B7DA8A0CD39Q35660696-0DBBE926-4C36-417E-AA7D-718198411189Q35664913-5E174D8D-C0E3-4240-9FD1-948CBDD44E5FQ36866183-B92A9D03-09FF-4868-8E65-7EA7222D3F55Q37222127-17841901-DF25-4737-BD9C-3ED1B3FFE0F2Q37716437-7160AA33-FA6A-4417-9C84-9A1491D7C2F9Q38266149-F895A4DD-26B0-4A30-8DE5-16ACFD47832AQ38318683-0363B9B9-0687-4063-9C76-669C8D83D4B4Q38670099-17968B6B-6456-4D23-BE4C-26925F9E9F28Q39005601-27B41DD7-3A0B-4C1C-A30D-CB6D360E21B1Q39024097-5AE15082-3DD5-45FE-BB6E-619338D63772Q39661584-1182BC7B-D656-41F0-9A83-68770640B44EQ40056727-66AE77AD-E03D-472E-8EBA-F0E6AECB1290Q52752658-F501710D-3198-4C5C-B10D-DFA7A40B606EQ55492453-47653C0B-45B3-4154-8B1A-83C740A00824Q56888862-95139626-F579-416A-82EC-8297949E2EF5
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Tumor-infiltrating lymphocytes in melanoma.
@ast
Tumor-infiltrating lymphocytes in melanoma.
@en
type
label
Tumor-infiltrating lymphocytes in melanoma.
@ast
Tumor-infiltrating lymphocytes in melanoma.
@en
prefLabel
Tumor-infiltrating lymphocytes in melanoma.
@ast
Tumor-infiltrating lymphocytes in melanoma.
@en
P2860
P1476
Tumor-infiltrating lymphocytes in melanoma.
@en
P2093
Kim Margolin
Sylvia Lee
P2860
P2888
P304
P356
10.1007/S11912-012-0257-5
P577
2012-10-01T00:00:00Z